🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨 BIG NEWS! 🚨 We showed strong results from the VICTORI study at #AACR25 (Emma Titmuss, BC Cancer), which utilized our ultrasensitive NeXT Personal® assay in detecting early signs of residual or recurrent in a cohort of 71 patients with resectable stage I-IV #ColorectalCancer

📑 NEW ARTICLE in @Genomeweb! Check out the latest article which highlights our amazing new data presented during #AACR25. • VICTORI study: demonstrated the value of our ultrasensitive #MRD platform in #ColorectalCancer. • #TRACERx study: further research showed that

Check out these talks at #ISMRC2025! 🗣 • #TRACERx insights into ultrasensitive minimal residual disease detection presented by Prof. Charles Swanton (#LungCancer) • Ultrasensitive ctDNA profiling in #Melanoma undergoing immune-checkpoint inhibition presented by Prof.

“Cancer does not define me, but it is a part of who I am. It is a part of my story. This is Mary 2.0. Now’s my second chance.” We’re incredibly honored to share Mary Royal’s story as a breast cancer survivor, and how our NeXT Personal® circulating tumor DNA (ctDNA) test gave

🏙️ We’re excited to be back in Chicago for #ASCO25 next week! 🧬 Our team of experts is ready chat about our innovative technology for ultrasensitive ctDNA detection and advanced tissue analysis. Visit us at booth # 31137 from May 31 to June 2. 📣 If you’re at ASCO 2025, make

We’re pleased to announce an evening celebration for our patients, partners, collaborators, and customers during #ASCO25! The evening will feature live entertainment, beverages and heavy hors d’oeuvres with amazing panoramic views of the Chicago skyline. Plus, a speaking

⏯️ Check out this new video showing the ability of NeXT Personal® to consistently achieve highly sensitive limits of detection (LOD) across a large number of patient samples across many solid tumor types, including samples of poor quality: • NeXT Personal demonstrated a

We're only a couple days away from our evening celebration! Space will be limited, make sure to RSVP soon. You can register for the event here: bit.ly/3T0DlEx.

#ASCO25: PREDICT-DNA study shows ctDNA testing after neoadjuvant chemo can identify HER2+/TNBC patients at highest recurrence risk - particularly important for TNBC cases. Could help identify who needs more treatment post-surgery. UW Medicine Fred Hutch Cancer Center

🚨NEW DATA from #ASCO25! PREDICT DNA and SCANDARE studies highlight capabilities of ultrasensitive NeXT Personal® #ctDNA blood test for monitoring and predicting neoadjuvant therapy (NAT) response in triple negative breast cancer (#TNBC), one of the most aggressive types of

🚨NEW results from #ASCO25: Our ultrasensitive NeXT Personal® #ctDNA blood test detected cervical cancer relapse up to ~16 months ahead of imaging in a cohort of 186 patients with locally advanced #CervicalCancer in latest CALLA phase 3 study analysis. Key findings: •

No Doubt: Ultrasensitive ctDNA Blood Test Sets Bar for MRD Cervical Cancer Phase 3 results indicate that the ultrasensitive NeXT Personal #ctDNA enables earlier detection in #cervicalcancer with high recurrence rates UC San Diego Personalis, Inc. hubs.li/Q03rvfz40

📊 We presented groundbreaking NEW data in locally advanced #CervicalCancer (LACC) at #ASCO25. 🧬 Our ultrasensitive ctDNA blood test, NeXT Personal®, detected cancer relapse up to ~16 months ahead of imaging in a cohort of 186 patients with LACC. 📑 Read the following articles

This month and year-round, we are proud to be an ally to the LGBTQIA+ community. At Personalis, we welcome, encourage, support, and celebrate diverse voices and experiences. We are committed to creating a workplace where everyone feels safe and supported. #PrideMonth